1. Home
  2. TGTX vs SOLS Comparison

TGTX vs SOLS Comparison

Compare TGTX & SOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

N/A

Current Price

$64.36

Market Cap

8.5B

Sector

Health Care

ML Signal

N/A

Logo Solstice Advanced Materials Inc.

SOLS

Solstice Advanced Materials Inc.

N/A

Current Price

$64.48

Market Cap

9.2B

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
TGTX
SOLS
Founded
1993
2025
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Aerospace
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
8.5B
9.2B
IPO Year
2008
2025

Fundamental Metrics

Financial Performance
Metric
TGTX
SOLS
Price
$64.36
$64.48
Analyst Decision
Buy
Buy
Analyst Count
8
10
Target Price
$69.43
★ $77.90
AVG Volume (30 Days)
1.8M
★ 2.5M
Earning Date
11-09-2026
11-04-2026
Dividend Yield
N/A
★ 0.47%
EPS Growth
★ 1746.67
N/A
EPS
0.52
★ 1.78
Revenue
$2,785,000.00
★ $3,886,000,000.00
Revenue This Year
$61.95
$8.36
Revenue Next Year
$35.55
$5.95
P/E Ratio
$120.60
★ $35.86
Revenue Growth
N/A
★ 3.08
52 Week Low
$26.76
$42.77
52 Week High
$68.03
$90.80

Technical Indicators

Market Signals
Indicator
TGTX
SOLS
Relative Strength Index (RSI) 60.53 54.61
Support Level $52.12 $55.64
Resistance Level $63.60 $65.33
Average True Range (ATR) 3.52 2.86
MACD 0.14 0.31
Stochastic Oscillator 64.62 72.16

Price Performance

Historical Comparison
TGTX
SOLS

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

About SOLS Solstice Advanced Materials Inc.

Solstice Advanced Materials is a diversified specialty chemicals company created in late 2025 after being spun off from Honeywell. It sells chemicals and materials to a wide range of end markets. Its largest product category is refrigerants used in heating, ventilation and air conditioning systems, and autos, where Solstice sells low global warming potential refrigerants. The company also sells materials used for building and construction, semiconductor production, healthcare packaging, and defense. Additionally, Solstice runs the only US uranium conversion business currently in operation.

Share on Social Networks: